341 results on '"Heasley, Lynn E."'
Search Results
2. Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response
3. EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment
4. Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response
5. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
6. Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib
7. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines
8. A Functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes
9. A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes
10. Supplementary Figure 1 from Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes
11. Supplemental File 3 from Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes
12. Supplementary Figure 1 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
13. Data from Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes
14. Supplementary Figure Legends from Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes
15. Supplemental File 2 from Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes
16. Supplementary Figure 5 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
17. Supplementary Figure 6 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
18. Supplementary Figure 4 from Hypoxia Regulates Alternative Splicing of HIF and non-HIF Target Genes
19. Supplementary Figure 3 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
20. Data from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
21. Supplementary Figure 7 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
22. Data Supplement from Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
23. Supplementary Table 1 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
24. Supplementary Figure 2 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
25. Data from Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
26. Supplementary Figure 8 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
27. Supplementary Figure 4 from The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
28. Figure S5 from FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers
29. Data from Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells
30. Supplementary Figures 1-5, Tables 1-2 from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
31. Supplementary Tables 2 - 4 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
32. Supplementary Tables 1-2 from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
33. Supplementary Figure Legends 1-5 from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
34. Data from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
35. Figures S1-9 and Legends from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
36. Supplementary Tables 1-2, Figures 1-2 from Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells
37. Supplementary Figure Legends, Figures 1 - 7 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
38. Supplementary Table 1 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
39. Data from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
40. Supplementary Table 5 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
41. Data from Protein Kinase C δ Is a Downstream Effector of Oncogenic K-ras in Lung Tumors
42. Data from Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC
43. Supplementary Methods, Figures S1-S12, Tables S1-S2 from Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC
44. Supplementary Figure 1 from Protein Kinase C δ Is a Downstream Effector of Oncogenic K-ras in Lung Tumors
45. Supplementary Figure 2 from Protein Kinase C δ Is a Downstream Effector of Oncogenic K-ras in Lung Tumors
46. Supplementary Figure Legends 1-2 from Protein Kinase C δ Is a Downstream Effector of Oncogenic K-ras in Lung Tumors
47. Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
48. Upregulation of complement proteins in lung cancer cells mediates tumor progression
49. Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response
50. Evaluation of KRASG12C Inhibitor Responses in Novel Murine KRASG12C Lung Cancer Cell Line Models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.